[144] IONIS PHARMACEUTICALS INC SEC Filing
Ionis Pharmaceuticals, Inc. filed a Form 144 notice reporting a proposed sale of 6,849 shares of common stock, with an aggregate market value of
Ionis Pharmaceuticals, Inc. ha presentato un avviso Form 144 segnalando una prevista vendita di 6,849 azioni ordinarie, con un valore di mercato complessivo di
Ionis Pharmaceuticals, Inc. presentó un aviso Form 144 informando una venta propuesta de 6,849 acciones comunes, con un valor de mercado agregado de
Ionis Pharmaceuticals, Inc.은 Form 144 공시를 제출하여 6,849 주의 보통주 매각 계획을 보고했고, 총 시가가
Ionis Pharmaceuticals, Inc. a déposé un avis Form 144 signalant une vente proposée de 6,849 actions ordinaires, pour une valeur marchande totale de
Ionis Pharmaceuticals, Inc. hat eine Form 144-Mitteilung eingereicht, in der ein geplanter Verkauf von 6,849 Stammaktien gemeldet wird, bei einem aggregierten Marktwert von
شركة Ionis Pharmaceuticals, Inc. قدمت إشعاراً
Ionis Pharmaceuticals, Inc. 已提交 Form 144 通知,报告拟议出售 6,849 股普通股,市场总值为
- Planned sale is modest: only 6,849 shares versus 159,391,229 outstanding
- Securities were acquired as RSUs on
01/15/2025 , indicating compensation-related origin - Recent prior sales disclosed (total 38,244 shares), showing transparency in insider transactions
- Concentrated recent selling: 38,244 shares sold in three transactions generating
$2,346,609 , which may be viewed as insider liquidity - No Rule 10b5-1 plan date provided in the notice, leaving uncertainty about pre-planned sale protection
Insights
TL;DR: Reported sales are routine insider liquidity from RSUs and consistent with Rule 144 disclosures.
The filing shows a planned sale of 6,849 shares (acquired as RSUs on
These items indicate insider liquidity rather than a single large block sale; compliance hinges on whether the trades follow a documented plan like Rule 10b5-1 and on the filer’s representation of no undisclosed material information. Monitor filing dates and any stated plan adoption date for clarity on pre-planned trading protection within the next weeks.
Ionis Pharmaceuticals, Inc. ha presentato un avviso Form 144 segnalando una prevista vendita di 6,849 azioni ordinarie, con un valore di mercato complessivo di
Ionis Pharmaceuticals, Inc. presentó un aviso Form 144 informando una venta propuesta de 6,849 acciones comunes, con un valor de mercado agregado de
Ionis Pharmaceuticals, Inc.은 Form 144 공시를 제출하여 6,849 주의 보통주 매각 계획을 보고했고, 총 시가가
Ionis Pharmaceuticals, Inc. a déposé un avis Form 144 signalant une vente proposée de 6,849 actions ordinaires, pour une valeur marchande totale de
Ionis Pharmaceuticals, Inc. hat eine Form 144-Mitteilung eingereicht, in der ein geplanter Verkauf von 6,849 Stammaktien gemeldet wird, bei einem aggregierten Marktwert von